MAIA Biotechnology
Business Services · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
444 W Lake St Ste 1700, Chicago, Illinoi...Phone Number
(312) 416-8592Website
www.maiabiotech.comRevenue
-Stock Symbol
MAIAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
5
1
About MAIA Biotechnology
MAIA Biotechnology Inc focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.Explore more
MAIA Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MAIA Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MAIA Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MAIA Biotechnology
MAIA Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if MAIA Biotechnology is spiking on competitors!
Product Launch: Get notified when MAIA Biotechnology launches new products
Earning: See what the market has to say on MAIA Biotechnology recently announced quarterly report
Funding: Get notified immidiatlly once MAIA Biotechnology has new funding data
Click to see if MAIA Biotechnology had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at MAIA Biotechnology
Find 2 more new buyers
Compare Similar Companies to MAIA Biotechnology
Compare insights from companies similar to MAIA Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MAIA Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MAIA Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MAIA Biotechnology.
MAIA Biotechnology financials insights
Gather financial insights about MAIA Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$62K
Stock Offering
$6.2M
2022
Stock Offering
$2.4M
2025
Multiple Rounds
$4.7M
MAIA Biotechnology Tech Stack
A closer look at the technologies used by MAIA Biotechnology
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Project
Product Management, Intellectual Property, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Regulations
MAIA Biotechnology News & Media
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology’s business, recent updates, management commentary, financial results, valuatioMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90.5% interim disease control rate (DCR) observed with combination therapyMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Part C domestic enrollment is underway at three clinical sites in the U.S.MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding MAIA Biotechnology
Sign Up For FreeTo access detailed company insights
MAIA Biotechnology Inc focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer ce... Read More
